Mangoceuticals, Inc. Announces Pricing Of $1.2M Public Offering Of 4M Shares Of Common Stock At A Price Of $0.30 Per Share
Mangoceuticals, Inc. Announces Pricing Of $1.2M Public Offering Of 4M Shares Of Common Stock At A Price Of $0.30 Per Share
Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated hair growth product ("GROW") and erectile dysfunction ("ED") drug ("Mango"), today priced its previously announced underwritten public offering of 4,000,000 shares of its common stock, par value $0.0001 per share, at a public offering price of $0.30 per share, for aggregate gross proceeds of $1,200,000 to the Company, prior to deducting underwriting discounts and commissions and other offering expenses payable by the Company. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 600,000 shares of its common stock at the public offering price of $0.30 per share, less the underwriting discounts and commissions, to cover over-allotments, if any.
Mangoceuticals, Inc.（纳斯达克股票代码：MGRX）（“MangorX” 或 “公司”）是一家专注于通过安全的远程医疗平台开发、营销和销售各种男士健康和保健产品的公司，包括其独特配方的生发产品（“GROW”）和勃起功能障碍（“ED”）药物（“Mango”）今天对其先前宣布的承销公开发行4英镑进行了定价在此之前，该公司发行了00万股普通股，面值为每股0.0001美元，公开发行价格为每股0.30美元，总收益为120万美元扣除承保折扣和佣金以及公司应支付的其他发行费用。此外，公司已向承销商授予45天的期权，允许他们以每股0.30美元的公开发行价格（减去承销折扣和佣金）额外购买最多60万股普通股，以弥补超额配股（如果有）。
The offering is expected to close on or about December 19, 2023, subject to customary closing conditions.
此次发行预计将于2023年12月19日左右结束，但须遵守惯例成交条件。
The Company intends to use the net proceeds from the offering to finance the marketing and operational expenses associated with the planned marketing of its Mango ED and GROW hair growth products, to hire additional personnel to build organizational talent, to develop and maintain software, and for working capital and other general corporate purposes.
公司打算将本次发行的净收益用于支付与其Mango ED和GROW生发产品的计划营销相关的营销和运营费用，雇用更多人员来培养组织人才，开发和维护软件，以及用于营运资金和其他一般公司用途。
Boustead Securities, LLC is acting as the sole underwriter for the offering.
Boustead Securities, LLC是本次发行的唯一承销商。